Functional Detection of Neutralizing Antibodies Against Anti-Cancer Biotherapeutics
Newsletter

Functional Detection of Neutralizing Antibodies Against Anti-Cancer Biotherapeutics

Assessing neutralizing antibodies is a critical component of immunogenicity evaluation, and  functional, MoA‑reflective cell-based assays remain the gold standard. However, developing robust cell-based NAb assays remains challenging. 

This poster, created in collaboration with Bio‑Rad and leveraging their recombinant monoclonal NAb controls, highlights how iLite® ADCC, ADCP, and CDC bioassays provide robust, fit‑for‑purpose tools for detecting neutralizing antibodies against therapeutics such as Rituximab and Daratumumab.

Download the poster to see how these functional assays deliver dose‑dependent NAb detection, strong specificity, and reliable patient‑sample compatibility to support clinical immunogenicity programs.

Complete the form to download the poster